Adult survivors of childhood or adolescent osteosarcoma require ongoing medical follow-up in order to monitor for potentially life-threatening consequences of therapy, including second cancers and anthracycline cardiotoxicity. In the future, additional knowledge of tumor biology will likely change staging methods and allow intensive therapy to be given only to those most likely to benefit from it ; those with less risk of relapse may require less toxic therapy and still achieve acceptable levels of survival.
|Original language||English (US)|
|Number of pages||4|
|Journal||Cancer treatment and research|
|State||Published - Jan 1 1993|
ASJC Scopus subject areas
- Cancer Research